10-Q: Bio-Path Holdings Reports Q3 2024 Results, Provides Clinical Trial Updates and Addresses Nasdaq Compliance

Bio-Path Holdings reported its Q3 2024 financial results, provided updates on its clinical trials, and addressed its ongoing efforts to regain compliance with Nasdaq listing requirements.

Summary

• Bio-Path Holdings, a clinical-stage oncology company, reported a net loss of $2.1 million for the three months ended September 30, 2024, and a net loss of $7.1 million for the nine months ended September 30, 2024.
• The company's research and development expenses decreased to $1.3 million for the quarter and $5.5 million for the nine months, primarily due to reduced manufacturing costs.
• General and administrative expenses increased to $1.3 million for the quarter and $3.9 million for the nine months, driven by higher legal fees and personnel costs.
• The company's cash balance was $0.6 million as of September 30, 2024, and it has raised additional capital through various offerings.
• Bio-Path is actively progressing its clinical trials for prexigebersen, BP1002, and BP1001-A, with updates provided on patient enrollment and interim data.
• The company is also working to regain compliance with Nasdaq listing requirements after receiving a delisting determination letter.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the clinical trial data is promising and the company has raised additional capital, the ongoing losses, low cash balance, and Nasdaq delisting notice create significant uncertainty. The sentiment is cautiously optimistic due to the potential of the drug candidates but tempered by the financial and regulatory challenges.

Positives

• The company has made progress in its clinical trials, with positive interim data reported for prexigebersen in AML and successful completion of dose cohorts for BP1002 and BP1001-A.
• The company has raised additional capital through various offerings, including a private placement in October 2024, which will provide additional funding for operations.
• The company is exploring new indications for its drug candidates, such as BP1001-A for obesity, which could expand its market potential.
• The company has a strong intellectual property portfolio with composition of matter and method of use patents for its drug products.

Negatives

• The company continues to incur significant operating losses, with a net loss of $7.1 million for the nine months ended September 30, 2024.
• The company's cash balance is low at $0.6 million as of September 30, 2024, raising concerns about its ability to fund operations.
• The company received a delisting determination letter from Nasdaq, indicating a failure to meet minimum stockholders' equity requirements.
• The company is dependent on raising additional capital to fund its operations and clinical trials, which may not be available when needed or on favorable terms.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• The company faces significant risks and uncertainties associated with drug development, including clinical trial delays, regulatory hurdles, and competition.
• The company's common stock is subject to volatility and is thinly traded.
• The company's ability to regain and maintain compliance with Nasdaq listing standards is uncertain.
• The company relies on third parties for manufacturing and conducting clinical trials, which could lead to delays or disruptions.

Future Outlook

The company expects to continue to incur significant operating expenses and will require substantial additional capital to fund its operations. The company plans to continue enrollment in its clinical trials and pursue FDA expedited programs. The company is also evaluating whether to expand its clinical trial in Europe.

Management Comments

• The company believes that adding prexigebersen to the treatment combination of decitabine and venetoclax could lead to improved efficacy in AML patients.
• The company believes that BP1002 may be a potential treatment for venetoclax-relapsed AML patients.
• The company believes development of BP1001-A for the treatment for obesity and related metabolic diseases could be accelerated given the large amount of safety data from BP1001-A treatment of patients with solid tumors.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, focusing on oncology treatments. The company's approach of using RNAi nanoparticle technology for targeted protein inhibition is aligned with current trends in drug development. The company's focus on AML and other cancers is in line with the significant unmet medical needs in these areas.

Comparison to Industry Standards

• The company's reported CR/CRi rate of 86% for newly diagnosed AML patients in the prexigebersen trial is significantly higher than the 54-74% range reported for frontline decitabine and venetoclax combination therapy in publications.
• The company's reported CR/CRi rate of 57% for relapsed/refractory AML patients in the prexigebersen trial is significantly higher than the 12-52% range reported for decitabine and venetoclax combination therapy in publications.
• The company's approach of combining prexigebersen with decitabine and venetoclax is a novel approach in the treatment of AML, which is a competitive space with companies such as AbbVie and Genentech developing treatments in this area.
• The company's development of BP1002 for Bcl-2 inhibition is similar to the approach of companies like AbbVie and Roche, who have developed venetoclax, a Bcl-2 inhibitor.
• The company's development of BP1003 for STAT3 inhibition is in line with the industry's interest in targeting this pathway for cancer treatment, with companies like Bristol Myers Squibb and AstraZeneca also exploring this area.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, stock price volatility, and the risk of delisting from Nasdaq.
• Employees are impacted by the company's financial stability and the potential for changes in operations.
• Patients are impacted by the progress of clinical trials and the potential for new treatment options.
• Creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• The company plans to continue enrollment in its clinical trials for prexigebersen, BP1002, and BP1001-A.
• The company expects to advance to the next planned higher dose of 90 mg/m2 for BP1002 in the fourth quarter of 2024.
• The company plans to complete enrollment in cohorts 1 and 2 of the prexigebersen trial in 2026.
• The company plans to pursue FDA expedited programs for Fast Track designation for prexigebersen.
• The company is preparing for preclinical development evaluating BP1001-A for the treatment of obesity.
• The company will present a plan to regain compliance with Nasdaq listing requirements at a hearing on November 5, 2024.

Key Dates

Keywords

oncology, RNAi, nanoparticle, drug development, clinical trials, prexigebersen, BP1002, BP1003, BP1001-A, AML, lymphoma, solid tumors, Nasdaq, capital raise, biotechnology